NABI biopharmaceutical's NIH link

StaphVAX, produced by North American Biologicals (NABI) Biopharmaceuticals, is a Staphylococcus aureus polysaccharide conjugate vaccine currently in phase 3 trials in the US. It is based on technology developed in the lab of John Robbins at the National Institute of Child Health and Human Development (NICHD), one of the NIH institutes that has a large portfolio of childhood vaccines. The vaccine technology was licensed to Univax Biologics, then a small local firm, which also recruited a postdoctoral fellow from the NICHD lab.

The platform was further used to develop additional conjugated vaccines such as the NicVax as an aid to smoking cessation. The products then proceeded to Univax, an incubator, and then further developed with a CRADA. From there, the product migrated through a merger with NABI, a publicly traded company.